435 Studies Now Enrolling
A prospective observational study in Cystic Fibrosis Patients with chronic Pseudomonas aeruginosa infection treated with TOBI Podhaler (tobramycin inhalation power) or other FDA approved inhaled antipseudomonal antibacterial drug
An study for patients with cystic fibrosis (CF) treated with TOBI Podhaler or other FDA approved inhaled antipseudomonal antibacterial drug
| Sponsor: | Novartis |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAP9053 |
| Contact: | Yudy Fernandez-Pau: 212-305-6309 / yf2190@cumc.columbia.edu |
Additional Study Information:
This study is for patients who have been prescribed tobramycin inhalation powder (TOBI Podhaler) or another inhaled medication used to treat cystic fibrosis patients whose lungs contain bacteria called Pseudomonas aeruginosa. The purpose of this research study is to assess how well TOBI Podhaler works on treating Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis (CF).
This study is closed
